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Prostate proliferation is dependent of androgens and many peptide hormones. Recent reports suggest that SSTR2 and SHP-1 were
two fundamental components on antiproliferative eﬀect of somatostatin. Many studies on SHP-1 revealed that the expression
of this protein was diminished or abolished in several of the cancer cell lines and tissues examined. However, it is necessary to
confront the cell lines data with real situation in cancer cases. Our studies have shown that epithelial expressions of both proteins,
SHP-1 and SSTR2, in normal and benign hyperplasia are localized in the luminal side of duct and acinar cells. Also, SSTR2 is
expressed in stromal cells. In malignant prostate tissue, SHP-1 was diminished in 28/45 cases or absent in 12/45 cases, whereas
SSTR2 epithelial was diminished in 38/45 cases or lost in only 2/45 cases. The intensity of immunostained was highly negative
correlated with Gleason grade for two proteins.
Copyright © 2009 Ariel Ernesto Cariaga-Martinez et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Prostate cancer is one of the most common malignancies
among men in the Western world and is a great health prob-
lem in many countries. As the tumor is initially androgen
dependent in the majority of cases, endocrine manipulation
is a ﬁrst-line therapy for metastatic and locally advanced
cancer and often achieves remission or stabilization of the
disease [1]. However, this remission period is invariably fol-
lowed by tumor relapse, and the available treatment options,
based on cytotoxic chemotherapy or aromatase inhibitors,
are only palliative. Finally, patients with metastasic prostate
cancer develop an androgen refractory phenotype that leads
to disease progression and eventual death [2].
The prostate is not exclusively dependent on androgens,
but also on additional factors of paramount importance
for maintaining normal prostatic function that play a role
in pathological conditions development. In this sense, the
importance of peptide hormones, growth factors, autocrine-
paracrine regulatory loops, and stromal-epithelial interac-
tions is now widely recognized [3].
Protein tyrosine phosphorylation is regulated in the
cell by the opposing activities of two enzymes: protein
tyrosine kinases (PTKs), which transfer phosphate from
ATP to substrate proteins, and protein tyrosine phosphatases
(PTPs), which remove it. Functionally, the most important
eﬀect of tyrosine phosphorylation is to create high-aﬃnity
binding sites for other proteins containing small modular2 Advances in Urology
phosphotyrosine- (pTyr-) binding domains, most notably
S r ch o m o l o g y2( S H 2 )d o m a i n s[ 4]. Any deviation in
balance between PTP and PTK can promote abnormal cell
proliferationanddiﬀerentiationtherebyresultingindiﬀerent
kinds of diseases [5–7]. SHP-1 (PTPN6) is one of the most
important component from this equilibrium and decreased
activity, gene mutation or gene deletion, leading to an
increase in tyrosine-phosphorylated proteins in cells with
pathological consequences [8–11].
Somatostatin (SST) was described initially as a secre-
tory product of the hypothalamus acting as a potent
inhibitor of GH secretion [12]. Subsequently, high den-
sities of SST-producing neuroendocrine cells have been
localized throughout the central and peripheral nervous
systems, in the endocrine pancreas and in the gut, and
to a lower extent in the thyroid glands, adrenals glands,
submandibular glands, kidneys, liver, colon, rectum, small
intestine, stomach, placenta, and prostate [13, 14]. SST is
classically known to inhibit the secretion of a wide range
of hormones, exocrine glands, and gastrointestinal motility.
Among other ﬁndings is the inhibition of immunoglobulin
synthesis and lymphocyte proliferation in lymphoid tissues
[15]. Last but not least, SST has revealed an antiproliferative
potential, reversing the impact of mitogenic signals delivered
by substances such as epidermal growth factor (EGF)
and somatomedin C/insulin-like growth factor-1 (IGF-1)
(reviewed in [16]). These actions are mediated by a family
of seven transmembrane (TM) domain G-protein-coupled
receptors that comprise ﬁve distinct subtypes (termed
SSTR1 to 5). SSTRs are widely expressed in many tissues,
frequently as multiple subtypes that coexist in the same
cell [14]. The ﬁve receptors share common signaling path-
ways such as the inhibition of adenylate cyclase, activation
of phosphotyrosine phosphatase (PTP), and modulation
of mitogen-activated protein kinase (MAPK) through G-
protein-dependentmechanisms.Amongsomatostatinrecep-
tors, SSTR2 has been found to play a critical role in the
n e g a t i v ec o n t r o lo fc e l lg r o w t ha n dt oa c ta sat u m o r
suppressor gene for pancreatic cancer [17] and in medullary
thyroid carcinoma [18]. Many reports suggest that SHP-
1 may participate in the negative regulation of cellular
proliferation by SST [19, 20] and other peptides like AT-
II [21–24]. Interestingly, the presence of SHP-1 (PTPN6)
was identiﬁed in rat prostate [25] and in human prostate
[20].
Extensive studies on SHP-1 protein and mRNA revealed
that the expression of SHP-1 protein was diminished or
abolished in most of the cancer cell lines and tissues
examined(reviewedin[26]).Similarly,growthofcancercells
was suppressed after introducing the SHP-1 gene into the
corresponding cell lines [27, 28]. These data suggest that
SHP-1 can play either negative or positive roles in signal
transduction pathways regulation [29, 30]. Dysfunction in
S H P - 1r e g u l a t i o nc a nc a u s ea b n o r m a lc e l lg r o w t ha n d
induce diﬀerent kinds of cancers. These ﬁndings support
the hypothesis that the SHP-1 gene functions as a tumor
suppressor.
On the other hand, some studies demonstrate variations
on SSTR2 distribution on tumor and normal specimens and
these associations with histological grade, proliferation, and
treatment of tumors [31–34].
The aim of this study is evaluate the expression of both
SSTR2 and SHP-1 (PTPN6) in normal prostate and their
variation through tumoral progression in human prostate
cancer (diﬀerent Gleason scores).
2.MaterialsandMethods
2.1. Tissue Samples. Human prostate tissues were obtained
from transrectal needle biopsies, transurethral resection, and
retropubic or radical prostatectomy, from patients attend at
“Dr. Ram´ on Madariaga” Public Hospital Pathology Service
from Posadas, Misiones. The tissues were used in the
experiments after approval by the local ethical committee.
Tissues were ﬁxed in formalin and embedded in paraf-
ﬁn blocks. Sections were cut at 4μm and stained with
hematoxylin-eosin for histological diagnosis, with additional
sections cut for immunostaining.
Specimens were graded according to the original report
Gleason grading and classiﬁed with specimens with high-
grade adenocarcinomas zones represented by Gleason grade
4o r5( n = 20); specimens with intermediate-grade
adenocarcinomas zones represented by Gleason grade 3
(n = 13); specimens with low-grade adenocarcinomas zones
represented by Gleason grade 1 or 2 (n = 12).
2.2. Immunohistochemistry. The antibodies against for SHP-
1 (sc-287, Santa Cruz Biotechnology, Inc) and SSTR2 (sc-
25676, Santa Cruz Biotechnology, Inc) were used. The
immunostaining was performed by using the Univer-
sal DakoCytomation Labelled Streptavidin-Biotin2 System,
Horseradish Peroxidase (LSAB2 System - HRP, DAKO),
and according to manufacturer’s protocol. Specimens of
hyperplasic prostate and leukocytes, known to express SHP-
1 were used as positive controls. Primary antibody was
replaced with buﬀer as a negative control of immunostained
tissues.
After deparaﬃnization and rehydration sections were
treated with 3% hydrogen peroxide for 5 minutes. After that,
sections were incubated with primary antibody (Dilution
1:100) and left overnight in moist chambers at 4◦C followed
by sequential 30-minute incubation with a biotinylated
link antibody and 10-minute incubation peroxidase-labelled
streptavidin. After every antibody incubation, slides were
washed 3 times in TTBS buﬀer for 5 minutes. Staining is
completed after 5-minute incubation with 3-3  diaminoben-
zidine (DAB) Substrate Chromogen generating a brown-
colored precipitate at the antigen site. The sections were
then rinsed in distilled water for 5 minutes and coun-
terstained with 50% Mayer hematoxylin solution. After
dehydration, slides were mounted with Canada balsam
(Merck, Darmstadt, Germany). Slides were analyzed under
light microscopy and photographed.
2.3. Analysis of Immunostained Tissues. Gleason classiﬁca-
tion was established, and the immunostaining was compared
with prostate hyperplasia (positive control). MorphologicalAdvances in Urology 3
assessment of immunostained tissue was performed with
the aid of an occular grid, photographed and analyzed.
In cases showing zones with diﬀerent tumoral grade, the
immunostaining of each zone was analyzed.
Before slides observation, 3 representative photographies
of every tumoral grade in each case were analyzed. The
immunostaining intensity was classiﬁed as “+++” if the
intensity was the same of positive control, lightly reduced
(“++”) or low (“+”) if the intensity was less than positive
control, and negative in absence of immunoreactivity.
2.4. Statistic Analysis. The immunostaining and Gleason
grade were codiﬁed with numeric code. Correlation between
staining intensity and tumor grade for two proteins was eval-
uated by Pearson Correlation Coeﬃcient (r), that quantiﬁes
the direction and magnitude of correlation, using GraphPad
Prism version 4.00 for Windows, GraphPad Software, San
Diego, Calif, USA, http://www.graphpad.com.
3. Results
In the normal prostate tissues and hyperplasic prostate of
positive controls, the majority of epithelial cells showed
granular cytoplasmatic immunostaining for SHP-1 and
SSTR2 restricted to the luminal side of duct and acinar cells
(Figure 1). In this tissues, the immunostainings intensity was
classiﬁed as “+++” for the both of proteins. However, the
stromal shown expression only for SSTR2 with low intensity
classiﬁed as “+” in comparison with epithelial cells.
Most of cancer biopsies showed diﬀerent tumor grade
zones; SHP-1 and SSTR2 immunostaining were analyzed for
each zone and showed diﬀerent intensities in comparisons
with the control.
T h ep a t t e r n so fi m m u n o r e a c t i v i t yo fS H P - 1w e r en o r m a l
in only 5/45 cases (11%), diminished (“+” or “++”) in 28/45
cases (62%), and lost in 12/45 cases (27%) in agreement
to increase of Gleason grade with Pearson Correlation
Coeﬃcient of −0.8061 (Figure 2). This value indicates that
SHP-1 immunostain decreases as Gleason grade increases.
Frequently, high-grade adenocarcinomas zones, repre-
sented by Gleason grade 4 or 5, were negative in 11/20
cases or showed low SHP-1 expression (“+”) in 8/20 cases.
Intermediate-grade adenocarcinomas zones, represented by
Gleason grade 3, were negative only in 1/13 case, showed
low SHP-1 expression (“+”) in 5/13 cases or lightly reduced
expression (“++”) in 7/13 cases. However, low-grade ade-
nocarcinomas zones, represented by Gleason grade 1 or 2,
onlyshowedlightlyreducedSHP-1expression(“++”)in7/12
cases.
For SSTR2 the immunostained patterns were normal in
only 5/45 cases (11%), diminished (“+” or “++”) in 38/45
cases (84%), and lost in only 2/45 cases (4%) in agreement
to increase of Gleason grade with Pearson Correlation
Coeﬃcient of −0.7245 (Figure 3). This value indicates that
SSTR2 immunostain decreases as Gleason grade increases.
High-grade adenocarcinomas zones, represented by
Gleason grade 4 or 5, were negative in 1/20 case, showed
low SSTR2 expression (“+”) in 15/20 cases or lightly
reduced expression (“++”) in 4 cases. Intermediate-grade
adenocarcinomas zones, represented by Gleason grade 3,
showed low SSTR2 expression (“+”) in 11/13 cases or lightly
reducedexpression(“++”)in2/13cases.However,low-grade
adenocarcinomas zones, represented by Gleason grade 1 or
2, showed lightly reduced SSTR2 expression (“++”) in 6/12
c a s e so rw e r en o r m a l .
4. Discussion
The underlying mechanisms for tumoral prostate growth are
still poorly understood. It is now clear that PTPs play an
important role exerting negative or positive eﬀects in cancer-
related signaling pathways. Deviation from this equilibrium
can be induced by decreasing PTPs activity or expression
resulting in gene mutation or gene transcription downreg-
ulation [4, 28]. SHP-1 (PTPN6) and SHP-2 (PTPN11) are
key regulators that control the intracellular phosphotyrosine
level in lymphocytes and epithelial cells [7, 8, 10, 18, 20, 23,
27, 32, 35]. Some works demonstrated the antiproliferative
eﬀect of somatostatin and other peptides in human prostate
gland. For these peptides, the evidence has indicated that
protein tyrosine phosphatase SHP-1 plays a crucial role in
signal transduction mechanisms [26, 28]. Numerous studies
reported that all somatostatin receptor subtypes are able to
stimulate SHP-1 as the PTP involved in the somatostatin-
induced antiproliferative signal [13, 18–20, 23, 24, 26, 27].
In fact, previous studies have revealed that SHP-1 becomes
activated in response to somatostatin and SSTR2 association
and participates in negative regulation of mitogenic insulin
signaling [23, 24, 27].
Human prostate biopsies and studies of SHP-1 or SSTR2
expression in prostate carcinoma are limited (reviewed in
[26]). Our studies have shown the epithelial expressions of
both proteins, SHP-1 and SSTR2, in normal and benign
hyperplasia are localized in the luminal side of duct and
acinar cells. In addition, SSTR2 is expressed in stromal cells,
in agreement with previous studies [34, 36–40].
In malignant prostate tissue, our results showed that
SHP-1 immunoreactivity was diminished in 62% or was
absent in 26% of cases, whereas SSTR2 epithelial immunos-
taining was diminished in 84% or was absent in 3% of
cases. In addition, the intensity of immunostained and the
patterns of immunoreactive tumor cells were highly negative
correlated with Gleason grade for two proteins, indicating
that SHP-1 immunostain decreases than SSTR2 as Gleason
grade increases; that is the protein expression is lower in high
Gleason grade.
Previous studies had shown stronger distributions of
transcripts for SSTR2 in cancer prostate without correlation
between mRNA of SSTR2 and Gleason grade in appearance
contradiction with our results, which shows a diminished
protein expression with an increase in tumor Gleason grade
[36, 39]. These observations should be due to at mRNA
variations not is direct correlated with protein variations and
is probably that the protein expression is controlled at the
posttranscriptional level.
All observations have indicated that SSTR2 expression
and distribution in cancer prostate epithelium cells are4 Advances in Urology
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Figure 1: Immunohistochemical pattern of SHP-1 and SSTR2 on hyperplasic human prostate. The picture has shown the characteristic
SHP-1 (a) and SSTR2 (b) immunostaining on benign prostate hyperplasia hyperplasic. The intensity was classiﬁed as “+++” for comparison
with tumor glands.
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Figure 2: Distribution of SHP-1 on human prostate carcinoma. Photographies show characteristic pattern of SHP-1 immunostaining on
tumor zones: (a) Gleason H; (b) Gleason M; (c) Gleason L. (d) Percentages of cases classiﬁed for immunostaining intensity and Gleason
grade. Tissues were immunostained for SHP-1 was and the immunostaining intensity was classiﬁed as “+++” if the intensity was the same of
positive control, “++” or “+” if the intensity was less than positive control, and “−” if absent. Gleason L: low-grade adenocarcinomas zones,
Gleason grade 1 and 2. Gleason I: intermediate-grade adenocarcinomas zones, Gleason grade 3. Gleason H: high-grade adenocarcinomas
zone, Gleason grade 4 and 5.Advances in Urology 5
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Figure 3: Distribution of SSTR2 on human prostate carcinoma. Photographies show characteristic pattern of SSTR2 immunostaining
on tumor zones: (a) Gleason H; (b) Gleason M; (c) Gleason L. (d) Percentages of cases classiﬁed for immunostaining intensity and
Gleason grade. Tissues were immunostained for SSTR2 and the immunostaining intensity was classiﬁed as “+++” if the intensity was
the same of positive control, “++” or “+” if the intensity was less than positive control, and “−” if are absent. Gleason L: low-grade
adenocarcinomas zones, Gleason grade 1 and 2. Gleason I: intermediate-grade adenocarcinomas zones, Gleason grade 3. Gleason H: high-
grade adenocarcinomas zone, Gleason grade 4 and 5.
stronger and could cause an abnormal response of tumor
at somatostatin analogs treatment. For this, we think that
SSTR2 screening is necessary after incorporate therapy with
any somatostatin agonists like AN-238 [41–43].
Many studies suggest the important role of SHP-1 in
cell proliferation and analyzed the SHP-1 expression and its
contribution to the development of a malignant phenotype.
In lymphocytes, SHP-1 binds the immunoreceptor tyrosine-
based inhibition motif (ITIM) of the inhibitory receptors
(CD22, CD72, FcγRIIB, p70 NKB1, KIR) through its SH2
domains and subsequently activates or deactivates signals
regulating other pathways through tyrosine phosphatase
activity [26]. Dysfunction of SHP-1 induces lymphoma,
leukemia, and other related diseases. Delibrias et al. reported
the SHP-1 activity and expression diminished in many
EBV-positive Burkitt’s lymphomas cell lines [44]. Similarly,
the pattern of SHP-1 expression is greatly diminished
or suppressed in T lymphoma cell lines [35, 45, 46].
Decreased or suppressed SHP-1 expression in both malig-
nant transformation and tumor cell invasiveness in most
lymphoma/leukemia cell lines and in specimens from related
cancer patients is similar, thus supporting the crucial role of
SHP-1 in the pathogenesis in lymphomas [47].
However, established cell lines may not truly represent
the in vivo situation, and it is necessary to confront this
data with situations in biopsies of cancer cases. To determine
that the SHP-1 expression patterns in lymphoma/leukemia
specimens were essentially consistent to those observed
in the corresponding cell lines, Oka et al. analyzed 207
paraﬃn-embedded specimens of various malignant lym-
phomas/leukemia using cDNA expression array and tissue
microarray techniques. These results revealed that 100% of6 Advances in Urology
NK/T cell lymphoma specimens and more than 95% of
various types of malignant lymphoma specimens (DLL, FL,
HD, MCL, PT and ATLL) were negative for SHP-1 protein
expression [35].
Also, SHP-1 can activate an antiproliferation signaling
pathway in breast cancer cells [48], pancreatic cancer
[19], and prostate cancer [20]. In prostate carcinoma, the
androgen deprivation can also lead to development of a
negative growth-regulating loop involving antiproliferative
peptides like somatostatin. Previous studies revealed that
somatostatin is produced by human prostate cells lines PC-
3 and LNCaP, and this peptide is an important negative
regulator of the proliferation of these cell lines. These
cells have shown somatostatin receptor 2 (SSTR2) and
somatostatinreceptor5(SSTR5)expressions[20,28].Zapata
et al. clearly demonstrate that SHP-1 is a component
involved in thesomatostatin autocrine inhibitory loop: when
somatostatin secreted was blocked, the PC3 cell proliferation
increased and SHP-1 activity decreased; when somatostatin
was overexpressed, the PC3 cell proliferation decreased
and SHP-1 activity levels increased [20]. On the other
hand, Valencia et al. indicated that PC3 cell line expresses
other PTPs, such as SHP-2 and PTP1B, which could also
mediate the antiproliferative eﬀect of somatostatin in the
prostate [25]. However, this loop could be deﬁcient due to
low expression of SHP-1. Regardless the levels of peptides
receptors on prostate cancer (aﬀected or not by tumor
progression) [49], postreceptor signaling defects, such as
loss of SHP-1, may play a role in the pathogenesis of
prostate cancer by short-circuiting in signaling pathways of
these antiproliferative peptides with persistence of signals
generated by growth factors. In this sense, Douziech et al.
have demonstrated that SHP-1 expression conditioned the
somatostatin eﬀects over human pancreatic cancer growth,
the peptide antiproliferative eﬀects were not observed when
the enzyme was not expressed [23]. Here we observed a
diminished or lost expression of SHP-1 and SSTR2, the two
fundamental components of antiproliferative signal presents
in prostate cells, and we demonstrate that this is consistent
with advanced tumor grade.
5. Conclusion
Somatostatin receptor 2 (SSTR2) and SHP-1 tyrosine phos-
phatase are two fundamental components on antiprolifera-
tive eﬀect of somatostatin. Normal epithelial prostate cells
express SHP-1 and SSTR2, but we report that the levels
of expression were diminished or lost for two proteins in
advanced prostate cancer with an inverse ratio between
protein expression and Gleason grade of tumor.
Further studies are necessary to determine whether the
loss or up-regulation of others receptors by antiproliferative
peptides may contributes to prostate tumor development
and progression. Certainly, other parameters will have
to be further evaluated for determinate why SHP-1 and
SSTR2 expression diminish, establishing as a possible tumor
suppressor gene role of this proteins in human prostate and
determining the therapeutic potential of SHP-1 in clinical
outcome, that is, survival and tumor recurrence.
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